Table 2. Cycle 1: Univariate analysis of severe neutropenia.
| Variable | Severe neutropenia (25%) | p-value | |
| No (n = 55) | Yes (n = 18) | ||
| M dose, mg/kg (mean ± SD) | 0.39±0.14 | 0.43±0.12 | |
| Median (range) | 0.35 (0.15–0.89) | 0.46 (0.27–0.68) | |
| ≤0.40 | 37 (67%) | 6 (33%) | 0.01 |
| >0.40 | 18 (33%) | 12 (67%) | |
| Chemotherapy agents | 0.04 | ||
| M only | 30 (55%) | 11 (61%) | |
| M+ T/C | 20 (36%) | 2 (11%) | |
| M+ T + C | 5 (9%) | 5 (28%) | |
| Prior treatmenta | 0.77 | ||
| No | 24 (45%) | 7 (41%) | |
| Yes | 29 (55%) | 10 (59%) | |
M: melphalan; T: topotecan; C: carboplatin.
a
Data not available for 3 patients (2 had and 1 did not have severe neutropenia).